NASDAQ:GLUE
Monte Rosa Therapeutics, Inc. Stock News
$7.04
+0.450 (+6.83%)
At Close: Mar 27, 2024
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Friday, 22'nd Mar 2024
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
10:56am, Tuesday, 19'th Mar 2024
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 31'st Jan 2024
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
07:00am, Tuesday, 21'st Nov 2023
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that managemen
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Friday, 27'th Oct 2023
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that managemen
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
11:18am, Tuesday, 24'th Oct 2023
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
04:30pm, Tuesday, 30'th May 2023
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
07:30am, Friday, 03'rd Feb 2023
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the comp
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
11:18am, Wednesday, 25'th Jan 2023
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Dow Surges 150 Points; Crude Oil Falls Sharply
07:34pm, Monday, 14'th Nov 2022 Benzinga
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.
The Dow traded up 0.45% to 33,898.95 while the NASDAQ rose 0.11% to 11,335.52. The S
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
08:30pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
04:30pm, Monday, 31'st Oct 2022
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company wi
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
08:30pm, Thursday, 20'th Oct 2022 GlobeNewswire Inc.
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
04:30pm, Thursday, 20'th Oct 2022
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –
Albertsons Companies, Domino's Pizza And Other Big Gainers From Thursday
06:46am, Friday, 14'th Oct 2022 Benzinga
U.S. stocks closed higher on Thursday, with the Dow Jones jumping over 800 points. Here is the list of some big stocks recording gains in the previous session.
Nutex Health Inc. (NASDAQ: NUTX) jumped